Literature DB >> 24285567

Cannabinoids and the endocannabinoid system in lower urinary tract function and dysfunction.

Petter Hedlund.   

Abstract

AIMS: To review knowledge on cannabinoids and the endocannabinoid system in lower urinary tract function and dysfunction.
METHODS: Review of MEDLINE using defined search terms, and manual analysis. Articles published in English were included. RESULTS AND DISCUSSION: Components of the endocannabinoid system—cannabinoid (CB)receptor types 1 and 2, anandamide, and fatty acid amide hydrolase (FAAH), which degrades anandamide and related fatty-acid amides—have been located to lower urinary tract tissues of mice, rats, monkeys, and humans. Studies have located CB receptors in urothelium and sensory nerves and FAAH in the urothelium. CB receptor- and FAAH-related activities have also been reported in the lumbosacral spinal cord. Data on supraspinal CB functions in relation to micturition are lacking. Cannabinoids are reported to reduce sensory activity of isolated tissues, cause antihyperalgesia in animal studies of bladder inflammation, affect urodynamics parameters reflecting sensory functions in animals models, and appear to have effects on storage symptoms in humans. FAAH inhibitors have affected sensory bladder functions and reduced bladder overactivity in rat models. Cannabinoids may modify nerve-mediated functions of isolated lower urinary tract tissues.
CONCLUSIONS: Evidence suggests components of the endocannabinoid system are involved in regulation of bladder function, possibly at several levels of the micturition pathway. It is unclear if either CB receptor has a dominant role in modification of sensory signals or if differences exist at peripheral and central nervous sites. Amplification of endocannabinoid activity by FAAH inhibitors may be an attractive drug target in specific pathways involved in LUTS.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24285567     DOI: 10.1002/nau.22442

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  23 in total

1.  Liquid chromatography-mass spectrometry identification of serum biomarkers for nocturia in aged men.

Authors:  Satoru Kira; Takahiko Mitsui; Tatsuya Miyamoto; Tatsuya Ihara; Hiroshi Nakagomi; Yuka Hashimoto; Hajime Takamatsu; Masayuki Tanahashi; Masahiro Takeda; Norifumi Sawada; Karl-Erik Andersson; Masayuki Takeda
Journal:  World J Urol       Date:  2019-01-23       Impact factor: 4.226

Review 2.  The endocannabinoid system - a target for the treatment of LUTS?

Authors:  Petter Hedlund; Christian Gratzke
Journal:  Nat Rev Urol       Date:  2016-07-05       Impact factor: 14.432

3.  Attenuation of cystitis and pain sensation in mice lacking fatty acid amide hydrolase.

Authors:  Zun-Yi Wang; Peiqing Wang; Cecilia J Hillard; Dale E Bjorling
Journal:  J Mol Neurosci       Date:  2014-11-06       Impact factor: 3.444

Review 4.  Research Findings on Overactive Bladder.

Authors:  Phani B Patra; Sayani Patra
Journal:  Curr Urol       Date:  2015-05-20

5.  Activation of cannabinoid receptor 1 inhibits increased bladder activity induced by nerve growth factor.

Authors:  Zun-Yi Wang; Peiqing Wang; Dale E Bjorling
Journal:  Neurosci Lett       Date:  2015-01-06       Impact factor: 3.046

6.  Cannabinoid receptor expression in the bladder is altered in detrusor overactivity.

Authors:  Evangelia Bakali; John McDonald; Ruth A Elliott; David G Lambert; Douglas G Tincello
Journal:  Int Urogynecol J       Date:  2015-07-30       Impact factor: 2.894

Review 7.  Management of neurogenic bladder in patients with multiple sclerosis.

Authors:  Véronique Phé; Emmanuel Chartier-Kastler; Jalesh N Panicker
Journal:  Nat Rev Urol       Date:  2016-03-31       Impact factor: 14.432

8.  Anandamide transporter-mediated regulation of the micturition reflex in urethane-anesthetized rats.

Authors:  Masashi Honda; Naoki Yoshimura; Bunya Kawamoto; Katsuya Hikita; Kuniyasu Muraoka; Shogo Shimizu; Motoaki Saito; Michael B Chancellor; Atsushi Takenaka
Journal:  Int Urol Nephrol       Date:  2016-06-02       Impact factor: 2.370

9.  THC/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study.

Authors:  Giorgia Teresa Maniscalco; R Aponte; D Bruzzese; G Guarcello; V Manzo; M Napolitano; O Moreggia; F Chiariello; C Florio
Journal:  Neurol Sci       Date:  2017-10-19       Impact factor: 3.307

Review 10.  Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate.

Authors:  Stefan Ückert; George T Kedia; Dimitrios Tsikas; Annika Simon; Andreas Bannowsky; Markus A Kuczyk
Journal:  World J Urol       Date:  2019-09-10       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.